Real‐world comparative effectiveness, safety, and health care costs of oral anticoagulants in non‐valvular atrial fibrillation patients in the United States Department of Defense population

by | May 8, 2019 | Cardiovascular, Publication

Abstract Authors: Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Rosenblatt L, Liu X, HedeS, Nadkarni A, Shank T. Background: The ARISTOTLE trial demonstrated that apixaban had significantly lower rates of stroke/systemic embolism (SE) and major...

A real‐world observational study of hospitalization and health care costs among non‐valvular atrial fibrillation patients prescribed oral anticoagulants in the US Medicare population

by | May 6, 2019 | Cardiovascular, Publication

Abstract Authors: Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q,Baser O, Nadkarni A, Vo L. Background: Clinical trials have shown that direct oral anticoagulants (DOACs)-including dabigatran, rivaroxaban, apixaban, and...